Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/o7/96 \quad Origin: Appendix 5 \quad Amended o 1/o7/98, o 1/o9/99, o 1/o7/00, 30/09/01, 11/o3/02, o 1/o1/03, 24/10/05, o 1/o8/12 \\ Introduced o 1/o7/96 \quad Origin: Appendix 5 \quad Amended o 1/o7/98, o 1/o9/99, o 1/o7/00, 30/09/01, 11/o3/02, o 1/o1/03, 24/10/05, o 1/o8/12 \\ Introduced o 1/o7/96 \quad Origin: Appendix 5 \quad Amended o 1/o7/98, o 1/o9/99, o 1/o7/00, 30/09/01, 11/o3/02, o 1/o1/03, 24/10/05, o 1/o8/12 \\ Introduced o 1/o7/98, o 1/o9/99, o 1/o7/00, 30/09/01, 11/o3/02, o 1/o1/03, 24/10/05, o 1/o8/12 \\ Introduced o 1/o7/98, o 1/o7/00, 30/09/01, o 1/o7/00, 30/09/01, o 1/o7/00, o 1/o7$

Name of entity

LEXIUM INTERNATIONAL GROUP LIMITED					
BN 1 064 8	BN 1 064 820 408				
Ve (the	e entity) give ASX the following	information.			
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).					
1	⁺ Class of ⁺ securities issued or to be issued	(1) Ordinary Fully Paid Shares			
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	(1) 150,000			
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	(1) Ordinary Fully Paid Shares			
3	(eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price	(1) Ordinary Fully Paid Shares			

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	(1) Yes
5	Issue price or consideration	(1) \$91,500
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	(1) Shares issued in lieu of incentive payment for sales achievement
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	(1) 150,000
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 01/08/2012

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	Nil	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	(1) 2 March 2017	
o	N	NI1	+C1
8	Number and *class of all *securities quoted on ASX	Number	+Class Fully Paid Ordinary Shares
	(including the securities in section 2 if applicable)	303,484,198	Fully Paid Ordinary Shares

9 Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
2.250.000	2015 Dorformanco Dighto
3,250,000	2015 Performance Rights (Directors)
125,000	Unlisted Options expiring 9
<i>,</i>	November 2017 exercisable at
	\$1.2072
125,000	Unlisted Options expiring 9
	November 2017 exercisable at \$1.314
175,000	Unlisted Options expiring 31
-13,	August 2017 exercisable at \$0.18
6,916,626	Unlisted Options expiring 7 May
	2018 exercisable at \$0.75
500,000	Unlisted Options expiring 31
	December 2017 exercisable at \$0.70
1,000,000	Unlisted Options expiring 31
1,000,000	December 2017 exercisable at
	\$0.80
30,000	Unlisted Options expiring 31
	August 2017 exercisable at \$0.13
170,000	Unlisted Options expiring 31 August 2017 exercisable at \$0.16
1,500,000	Unlisted Options expiring 30
-,,,	September 2020 exercisable at
	\$0.75
1,125,000	Unlisted Options expiring 31
	August 2017 exercisable at \$0.18
1,125,000	Unlisted Options expiring 31 August 2017 exercisable at \$0.20
300,000	Unlisted Options expiring 04
<i>y</i> ,	November 2019 exercisable at
	\$0.75
300,000	Unlisted Options expiring 04
	November 2019 exercisable at
300,000	\$1.25 Unlisted Options expiring 04
300,000	November 2019 exercisable at
	\$1.75

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A		

Appendix 3B Page 4 01/08/2012

⁺ See chapter 19 for defined terms.

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of	N/A
	acceptances or renunciations	
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Despatch date	N/A

Appendix 3B Page 6 o1/08/2012

⁺ See chapter 19 for defined terms.

You need only complete this section if you are applying for quotation of securities Type of securities 34 (tick one) (a) Securities described in Part 1 (b) All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the 35 additional +securities, and the number and percentage of additional +securities held by those holders If the +securities are +equity securities, a distribution schedule of the additional 36 *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional *securities 37 Entities that have ticked box 34(b) 38 Number of securities for which ⁺quotation is sought

Part 3 - Quotation of securities

Class of *securities for which

quotation is sought

39

40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	N/A	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and ⁺ class of all	Number	+Class
'	$^+$ securities on ASX (including the		
	securities in clause 38)	N/A	N/A

Appendix 3B Page 8 o1/08/2012

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

	Nicholas Clark	
Sign here:	(Director/ Company secretary)	Date: 2/03/2017
Print name:	Nicholas Clark	
i illit manic.		••

01/08/2012 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated 286,087,714 Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue Add the following: 281.250 shares - issued 7 March 2016 Number of fully paid ordinary securities 93,750 shares - issued 22 March 2016 issued in that 12 month period under 187,500 shares - issued 1 April 2016 an exception in rule 7.2 250,000 shares - issued 18 April 2016 93,750 shares - issued 06 May 2016 93,750 shares - issued 06 May 2016 93,750 shares - issued 06 May 2016 250,000 shares - issued 11 May 2016 39,560 shares - issued 11 May 2016 93,750 shares - issued 01 June 2016 93,750 shares - issued 01 June 2016 250,000 shares - issued 01 June 2016 93,750 shares - issued 17 June 2016 93,750 shares - issued 17 June 2016 93,750 shares - issued 17 June 2016 93.750 shares - issued 17 June 2016 250,000 shares - issued 17 June 2016 95,000 shares - issued 28 June 2016 155,000 shares - issued 28 June 2016 100,000 shares - issued 15 July 2016 250,000 shares - issued 01 August 2016 83,333 shares - issued 12 August 2016 93,750 shares - issued 24 October 2016 1,000,000 shares - issued 04 November 2016 500,000 shares - issued 09 November 2016 500,000 shares - issued 09 November 2016 125,000 shares - issued 09 November 2016 100,000 shares - issued 09 November 2016 50,000 shares - issued 09 November 2016 375,000 shares - issued 30 December 2016 375,000 shares – issued 13 January 2017 200,000 shares - issued 10 February 2017 250,000 shares - issued 24 February 2017

01/08/2012 Appendix 3B Page 10

⁺ See chapter 19 for defined terms.

Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	285,713 shares issued 25 November 2016
Number of partly paid ordinary securities that became fully paid in that 12 month period.	Nil
Note:	
 Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	
"A"	293,071,320

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	43,960,698	

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 or rule 7.4

300,000 – Unlisted Options exercisable at \$0.75 per share (expiring 04 November 2019)

300,000 – Unlisted Options exercisable at \$1.25 per share (expiring 04 November 2019)

300,000 – Unlisted Options exercisable at \$1.75 per share (expiring 04 November 2019)

01/08/2012 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	9,677,420 – shares issued 20 April 2016 to raise capital 87,083 – shares issued 06 May 2016 for services rendered 17,591 – shares issued 06 May 2016 for services rendered 22,620 – shares issued 28 June 2016 for services rendered 40,831 – shares issued 24 October 2016 for services rendered 71,780 – shares issued 24 October 2016 for services rendered 100,000 – shares issued 25 November 2016 for services rendered 77,000 – shares issued 30 December 2016 for services rendered 20,000 – shares issued 30 December 2016 for services rendered		
	150,000 – shares issued 2 March 2017 in lieu of incentive payment		
"C"	11,164,325		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	43,960,698		

"A" x 0.15	43,960,698
Note: number must be same as shown in Step 2	
Subtract "C"	11,164,325
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	32,796,373
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 12 01/08/2012

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12-month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	N/A Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.

01/08/2012 Appendix 3B Page 13

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

Further to the announcement of Alexium International Group Limited (**Company**) on 2 March 2017 in relation to the placement of the following ordinary shares (**Shares**):

The Company has issued 150,000 shares in lieu of incentive payment for sales achievement.

the Company confirms that the Shares and warrants have been issued and, pursuant to section 708A(5)(e) of the *Corporations Act* 2001 (Cth) (**Corporations Act**), gives notice that:

- 1. the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; and
- as at the date of this notice, the Company has complied with:

the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

section 674 of the Corporations Act; and

as at the date of this notice, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

Appendix 3B Page 14 01/08/2012

⁺ See chapter 19 for defined terms.